DGX Quest Diagnostics Incorporated Common Stock
NYSE · Health Care · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 23, 2026
$233.33
· % 处于52周区间
· 高于低点
· 至高点
$171.1852周低点
$248.8452周高点
市值 (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
收入 (TTM)
$11.56B
DGX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$233.33
市值 (MRQ)
$25.67B
P/E (TTM)
24.8
EPS (TTM)
$9.42
收入 (TTM)
$11.56B
股息收益率
1.4%
ROE (TTM)
14.4%
负债/权益 (MRQ)
0.8
52周区间
$171–$249
DGX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2005年6月21日 | 2-for-1 | 正向 |
| 2001年6月1日 | 2-for-1 | 正向 |
关于 Quest Diagnostics Incorporated Common Stock 公司概况（来自维基百科）
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Health Care
行业Health Care
员工46000
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$11.04B2016-12-31 → 2025-12-31
EPS$8.752016-12-31 → 2025-12-31
自由现金流$1.36B2016-12-31 → 2025-12-31
净利率9.2%2016-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | DGX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | 24.85年均值 ≈17.7 | ≈17.7 | 23.3 | 低估 | |
| P/S (TTM) | 2.25年均值 ≈1.7 | ≈1.7 | 1.3 | 估值过高 | |
| 市净率 (MRQ) | 3.45年均值 ≈2.7 | ≈2.7 | 2.9 | 公允价值 | |
| EV / EBITDA (企业价值 / EBITDA) | 14.75年均值 ≈11.0 | ≈11.0 | 11.4 | 公允价值 | |
| 股价/自由现金流 (TTM) | 19.05年均值 ≈14.9 | ≈14.9 | · | · | |
| 市现率 (TTM) | 13.55年均值 ≈10.8 | ≈10.8 | 9.8 | 公允价值 | |
| EV / Revenue (市值/营收) | 2.85年均值 ≈2.2 | ≈2.2 | · | · | |
| EV / FCF (市值/自由现金流) | 22.95年均值 ≈18.8 | ≈18.8 | · | · | |
| 市净率（有形资产） (MRQ) | 4.4 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | DGX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | 14.1%5年均值 ≈15.6% | ≈15.6% | 8.3% | 顶尖 | |
| 息税折旧摊销前利润率 (TTM) | 19.1%5年均值 ≈20.2% | ≈20.2% | 8.8% | 顶尖 | |
| 税前利润率 (TTM) | 12.1%5年均值 ≈14.5% | ≈14.5% | 3.8% | 顶尖 | |
| 净利润率 (TTM) | 9.2%5年均值 ≈11.0% | ≈11.0% | 5.1% | 顶尖 | |
| ROA (TTM) | 6.5%5年均值 ≈8.0% | ≈8.0% | 4.0% | 顶尖 | |
| ROE (TTM) | 14.4%5年均值 ≈17.4% | ≈17.4% | 12.5% | 持平 | |
| ROIC | 9.2%5年均值 ≈11.0% | ≈11.0% | 9.2% | 持平 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | DGX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.85年均值 ≈0.8 | ≈0.8 | 0.4 | 高负债 | |
| 流动比率 (MRQ) | 1.65年均值 ≈1.2 | ≈1.2 | 1.4 | 流动性强 | |
| Quick Ratio (速动比率) | 0.85年均值 ≈1.0 | ≈1.0 | 0.8 | 流动性强 | |
| 长期负债/股东权益 (MRQ) | 0.75年均值 ≈0.7 | ≈0.7 | 0.7 | 高负债 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | DGX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 11.8%5年均值 ≈3.6% | ≈3.6% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 3.7%5年均值 ≈0.06% | ≈0.06% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 3.2% | · | · | · | |
| EPS YoY | 13.8%5年均值 ≈2.0% | ≈2.0% | · | · | |
| Net Income YoY (净利润同比增长) | 13.9%5年均值 ≈-1.4% | ≈-1.4% | · | · | |
| EPS CAGR 3Y (每股收益年复合增长率（3年）) | 3.2%5年均值 ≈-9.4% | ≈-9.4% | · | · | |
| EPS CAGR 5Y (每股收益年复合增长率（5年）) | -3.5% | · | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率（3年）) | 1.6%5年均值 ≈-12.8% | ≈-12.8% | · | · | |
| Net Income CAGR 5Y (净利润年复合增长率（5年）) | -7.1% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | DGX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.75年均值 ≈0.7 | ≈0.7 | 1.2 | 弱 | |
| Inventory Turnover (库存周转率) | 39.15年均值 ≈33.9 | ≈33.9 | 15.6 | 顶尖 | |
| Receivables Turnover (应收账款周转率) | 8.15年均值 ≈7.7 | ≈7.7 | 10.5 | 弱 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$239.9K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
股息 收益率、派息率、股息历史、5年CAGR
股息收益率1.4%
派息率35.6%
年度化派息≈$3.44
5年股息复合年增长率 (CAGR)≈7.4%
增长连胜≈14
| 除息日 | 金额 | 货币 | 收益率 |
|---|---|---|---|
| 七月 8, 2026 | $0.86 | USD | ≈1.6% |
| 四月 6, 2026 | $0.86 | USD | ≈1.6% |
| 一月 13, 2026 | $0.80 | USD | ≈1.8% |
| 十月 3, 2025 | $0.80 | USD | ≈1.8% |
| 七月 7, 2025 | $0.80 | USD | ≈1.8% |
| 四月 7, 2025 | $0.80 | USD | ≈1.9% |
| 一月 14, 2025 | $0.75 | USD | ≈2.0% |
| 十月 4, 2024 | $0.75 | USD | ≈2.0% |
| 七月 8, 2024 | $0.75 | USD | ≈2.1% |
| 四月 5, 2024 | $0.75 | USD | ≈2.2% |
| 一月 16, 2024 | $0.71 | USD | ≈2.1% |
| 十月 5, 2023 | $0.71 | USD | ≈2.3% |
| 七月 10, 2023 | $0.71 | USD | ≈2.0% |
| 四月 6, 2023 | $0.71 | USD | ≈1.9% |
| 一月 17, 2023 | $0.66 | USD | ≈1.8% |
| 十月 3, 2022 | $0.66 | USD | ≈2.1% |
| 七月 5, 2022 | $0.66 | USD | ≈1.9% |
| 四月 5, 2022 | $0.66 | USD | ≈1.9% |
| 一月 18, 2022 | $0.62 | USD | ≈1.8% |
| 十月 4, 2021 | $0.62 | USD | ≈1.7% |
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
3.6%
下次报告
十月 19, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 七月 20, 2026 | $3.12 | $2.85 | 9.3% |
| 2026年3月31日 | $2.50 | $2.37 | 5.5% | |
| 2025年12月31日 | $2.42 | $2.38 | 1.5% | |
| 2025年9月30日 | $2.60 | $2.53 | 2.8% | |
| 2025年6月30日 | $2.62 | $2.60 | 0.93% | |
| 2025年3月31日 | $2.21 | $2.17 | 1.7% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $65.18 | $61.06 | $56.82 | $53.09 | $54.15 | $50.82 | $42.41 | $38.64 | $36.45 | $33.78 | $32.76 | $29.87 | |
| Revenue / Share | $97.65 | $87.36 | $81.88 | $83.75 | $84.28 | $69.39 | $56.81 | $54.18 | $55.06 | $52.92 | $51.68 | $51.28 | |
| Cash Flow / Share | $16.69 | $11.81 | $11.26 | $14.56 | $17.45 | $14.74 | $9.14 | $8.63 | $8.39 | $7.53 | $5.59 | $6.47 | |
| Cash / Share | $3.82 | $4.95 | $6.18 | $2.84 | $7.33 | $8.71 | $8.96 | $1.00 | $1.01 | $2.62 | $0.93 | $1.33 | |
| Dividend / Share | · | · | · | · | · | · | · | · | $1.80 | $1.65 | $1.52 | $1.32 | |
| EPS (TTM) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | · | 112,000,000 | 112,000,000 | 111,000,000 | · | 112,000,000 | 111,000,000 | 111,000,000 | · | 112,000,000 | 112,000,000 | 112,000,000 | · | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | · | 113,000,000 | 113,000,000 | 113,000,000 | · | 113,000,000 | 112,000,000 | 112,000,000 | · | 114,000,000 | 114,000,000 | 113,000,000 | · | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $68.33 | $66.36 | · | $65.39 | $64.54 | $61.87 | · | $60.79 | $59.61 | $57.95 | · | $57.37 | $55.79 | $54.02 | · | $54.69 | |
| Revenue / Share | $27.17 | $25.85 | · | $24.92 | $24.43 | $23.47 | · | $22.02 | $21.40 | $21.12 | · | $20.13 | $20.51 | $20.63 | · | $21.07 | |
| Cash Flow / Share | · | $2.48 | · | · | · | $2.78 | · | · | · | $1.38 | · | · | · | $0.83 | · | · | |
| Cash / Share | $5.69 | $3.54 | · | $3.89 | $2.85 | $1.68 | · | $6.82 | $2.44 | $4.27 | · | $1.28 | $1.12 | $1.56 | · | $6.14 | |
| Dividend / Share | $0.86 | $0.86 | $0.80 | $0.80 | $0.80 | $0.80 | $0.75 | $0.75 | $0.75 | $0.75 | $0.71 | $0.71 | $0.71 | $0.71 | $0.66 | $0.66 | |
| EPS (TTM) | $9.42 | $9.05 | · | $8.52 | $8.35 | $7.91 | · | $7.44 | $7.41 | $7.43 | · | $6.71 | $6.92 | $6.83 | · | $10.16 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.56B | $11.28B | · | $10.85B | $10.52B | $10.16B | · | $9.54B | $9.35B | $9.29B | · | $9.30B | $9.49B | $9.60B | · | $10.29B | |
| Net Income TTM | $1.06B | $1.02B | · | $969M | $950M | $897M | · | $841M | $840M | $846M | · | $763M | $794M | $793M | · | $1.24B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 22.5 | 21.7 | · | 22.4 | 21.5 | 21.4 | · | 20.9 | 18.5 | 17.9 | · | 18.2 | 20.3 | 20.7 | · | 12.1 | |
| P/S | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.5 | 1.7 | 1.7 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 2.0 | 1.9 | 1.8 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Dividend Yield | 1.6% | 1.6% | · | 1.6% | 1.7% | 1.8% | · | 1.9% | 2.1% | 2.2% | · | 2.3% | 1.9% | 1.9% | · | 2.2% | |
| Earnings Yield | 4.4% | 4.6% | · | 4.5% | 4.7% | 4.7% | · | 4.8% | 5.4% | 5.6% | · | 5.5% | 4.9% | 4.8% | · | 8.3% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · | |
| Annual Payout | $363M | $357M | · | $347M | $342M | $336M | · | $327M | $323M | $319M | · | $309M | $307M | $305M | · | $307M |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| 营业利润率 % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| 净收入 | $992M | $871M | $854M | $946M | $2.00B |
| 稀释后每股收益 (EPS) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| 流动比率 | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| 速动比率 | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $1.36B | $909M | $864M | $1.31B | $1.83B |
机构持有人 (13F) 1170 家申报者 · $23.1B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
1170
持有价值
$23.1B
新仓位
118
已退出持仓
64
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 118 (-23 与上一季度对比) | 64 (-18 与上一季度对比) | 430 (+89 与上一季度对比) | 343 (-26 与上一季度对比) | +3.8M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| VANGUARD GROUP INC | $2497458052 | 14392082 | 10.79% | 股份 |
| BlackRock, Inc. | $1965923399 | 9275411 | 8.49% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1533117858 | 7233394 | 6.62% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1299474988 | 6131045 | 5.61% | 股份 |
| STATE STREET CORP | $1169252484 | 5516643 | 5.05% | 股份 |
| Boston Partners | $1004552880 | 4744473 | 4.34% | 股份 |
| JPMORGAN CHASE & CO | $748586197 | 3520438 | 3.23% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $662582607 | 3137873 | 2.86% | 股份 |
| MORGAN STANLEY | $521503271 | 2460497 | 2.25% | 股份 |
| EdgePoint Investment Group Inc. | $476372038 | 2247568 | 2.06% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $421376156 | 1988048 | 1.82% | 股份 |
| BANK OF AMERICA CORP /DE/ | $410151497 | 1935133 | 1.77% | 股份 |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400206122 | 1888207 | 1.73% | 股份 |
| WELLS FARGO & COMPANY/MN | $371171119 | 1751220 | 1.60% | 股份 |
| Davis Selected Advisers | $329781509 | 1555612 | 1.42% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $311037928 | 1467506 | 1.34% | 股份 |
| NORGES BANK | $298133109 | 1406620 | 1.29% | 股份 |
| FMR LLC | $296462102 | 1398735 | 1.28% | 股份 |
| Invesco Ltd. | $292303423 | 1379115 | 1.26% | 股份 |
| NORTHERN TRUST CORP | $238963873 | 1127454 | 1.03% | 股份 |
| GOLDMAN SACHS GROUP INC | $208282052 | 982694 | 0.90% | 股份 |
| UBS Group AG | $188403627 | 888906 | 0.81% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $173422135 | 818220 | 0.75% | 股份 |
| M&G PLC | $168677800 | 795650 | 0.73% | 股份 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $165917256 | 846603 | 0.72% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $163988047 | 773711 | 0.71% | 股份 |
| AMERIPRISE FINANCIAL INC | $161076730 | 759975 | 0.70% | 股份 |
| Legal & General Group Plc | $151986161 | 717085 | 0.66% | 股份 |
| Bank of New York Mellon Corp | $133388337 | 629339 | 0.58% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $131756386 | 621639 | 0.57% | 股份 |
| DEUTSCHE BANK AG\ | $124180445 | 585895 | 0.54% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $122662706 | 625894 | 0.53% | 股份 |
| Nuveen, LLC | $119503667 | 563830 | 0.52% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $109630811 | 517225 | 0.47% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $107196222 | 505762 | 0.46% | 股份 |
| Amundi | $105710274 | 498751 | 0.46% | 股份 |
| Woodline Partners LP | $102974000 | 485841 | 0.44% | 股份 |
| FIDUCIARY MANAGEMENT INC /WI/ | $102489906 | 483557 | 0.44% | 股份 |
| Artemis Investment Management LLP | $99175856 | 467921 | 0.43% | 股份 |
| CRAWFORD INVESTMENT COUNSEL INC | $97514204 | 460081 | 0.42% | 股份 |
| BARCLAYS PLC | $95107474 | 448726 | 0.41% | 股份 |
| ENVESTNET ASSET MANAGEMENT INC | $90834224 | 428564 | 0.39% | 股份 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $88822918 | 417715 | 0.38% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $83772178 | 395245 | 0.36% | 股份 |
| M.D. Sass, LLC | $76397960 | 360453 | 0.33% | 股份 |
| Qube Research & Technologies Ltd | $72783206 | 343398 | 0.31% | 股份 |
| MACKENZIE FINANCIAL CORP | $70641875 | 333295 | 0.31% | 股份 |
| Advisors Capital Management, LLC | $69429626 | 327575 | 0.30% | 股份 |
| CITIGROUP INC | $66888058 | 315584 | 0.29% | 股份 |
| Swiss National Bank | $65683305 | 309900 | 0.28% | 股份 |
激进投资者及 5%+ 股东 13 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 2011年5月18日 | · | 初始申报 | 并购/出售 | SEC |
| 未披露的报告人 | 2011年2月1日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人 | 2009年3月20日 | · | 初始申报 | · | SEC |
| GlaxoSmithKline plc ×2 申报 | 2008年9月18日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2007年2月16日 | · | 初始申报 | · | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 申报 | 2006年1月19日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2004年12月15日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2004年6月29日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2002年6月24日 | · | 初始申报 | 并购/出售 | SEC |
| 未披露的报告人 | 2002年5月22日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2002年4月12日 | · | 初始申报 | 并购/出售 | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 申报 | 2001年11月1日 | · | 初始申报 | 并购/出售 | SEC |
| 未披露的报告人 | 2001年5月14日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 52 位内幕人士 · 26 位高管 · 26 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 2026年9月1日 S | 122423 | 0 | 6 | $-17083502 |
| Surya N Mohapatra | Chairman, President & CEO | 2012年4月30日 F | 243713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 2026年7月22日 A | 33478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 2022年3月7日 F | 98981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 2013年3月5日 F | 126722 | 0 | 0 | $0 |
| Michael E Prevoznik | SVP & General Counsel | 2026年8月28日 M | 36557 | 0 | 6 | $-6649682 |
| Mark E Delaney | SVP & Chief Commercial Officer | 2026年7月28日 S | 10335 | 0 | 2 | $-1864971 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 2026年7月22日 L | 13557 | 0 | 2 | $-2167772 |
| Patrick Plewman | SVP for Diagnostic Services | 2026年7月22日 L | 15293 | 0 | 4 | $-2025174 |
| Catherine T. Doherty | EVP, Regional Businesses | 2026年3月5日 S | 67122 | 0 | 8 | $-6964749 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 2026年3月4日 F | 35196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 2024年9月24日 F | 4673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 2022年3月7日 F | 48391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 2021年2月17日 A | 29045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 2019年3月1日 F | 6261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 2018年3月8日 M | 31757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 2018年3月1日 G | 37760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2015年3月2日 F | 11837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 2014年2月13日 A | 19890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 2013年3月31日 F | 9569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 2012年2月29日 F | 89232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 2011年6月16日 M | 47150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 2007年2月12日 A | 12974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 2007年2月12日 A | 31079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 2007年2月12日 A | · | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 2004年2月28日 F | 49609 | 0 | 0 | $0 |
| Timothy C Wentworth | 董事 | 2026年10月1日 A | 1358 | 0 | 0 | $0 |
| Wright Lassiter III | 董事 | 2026年7月22日 L | 10323 | 0 | 0 | $0 |
| Vicky B Gregg | 董事 | 2026年7月22日 A | 18386 | 0 | 1 | $-239700 |
| Robert B Carter | 董事 | 2026年7月22日 L | 3864 | 0 | 0 | $0 |
| Timothy L Main | 董事 | 2026年7月22日 L | 22460 | 0 | 0 | $0 |
| Luis Diaz | 董事 | 2026年5月20日 A | 5196 | 0 | 0 | $0 |
| Tracey Doi | 董事 | 2026年5月20日 A | 7748 | 0 | 0 | $0 |
| Timothy M Ring | 董事 | 2026年5月20日 A | 31140 | 0 | 0 | $0 |
| Gary M Pfeiffer | 董事 | 2026年5月20日 A | 31005 | 0 | 1 | $-270317 |
| Gail R Wilensky | 董事 | 2023年5月17日 A | 20506 | 0 | 0 | $0 |
| Stephen H Rusckowski | 董事 | 2023年3月6日 F | 389597 | 0 | 0 | $0 |
| Helen Torley | 董事 | 2021年5月25日 A | 6260 | 0 | 0 | $0 |
| Daniel Stanzione | 董事 | 2020年11月23日 S | 28349 | 0 | 0 | $0 |
| Jenne K Britell | 董事 | 2018年6月4日 G | 14479 | 0 | 0 | $0 |
| Jeffrey M Leiden | 董事 | 2018年5月29日 S | 6000 | 0 | 0 | $0 |
| John B Ziegler | 董事 | 2017年2月22日 S | 16557 | 0 | 0 | $0 |
| John C Baldwin MD | 董事 | 2015年8月12日 S | 12949 | 0 | 0 | $0 |
| William F Buehler | 董事 | 2014年2月12日 M | 26225 | 0 | 0 | $0 |
| GSK plc | 董事 | 2011年1月31日 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | 董事 | 2010年5月6日 A | 9334 | 0 | 0 | $0 |
| William R Grant | 董事 | 2007年4月1日 A | 3334 | 0 | 0 | $0 |
| James F Flaherty III | 董事 | 2006年5月4日 A | 1667 | 0 | 0 | $0 |
| Kenneth D Brody | 董事 | 2004年4月28日 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | 董事 | 2004年4月1日 A | 2627 | 0 | 0 | $0 |
| Denise M Morrison | · | 2026年5月20日 A | 11929 | 0 | 0 | $0 |
| FREEMAN KENNETH W/NJ | · | 2004年12月14日 F | 216187 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 133 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IHF · iShares Trust | 3.75% | 212725 SH | 2026年9月11日 | 每日 |
| RW · EA Series Trust | 2.50% | 1865 NS | 2026年7月31日 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.62% | 61132 SH | 2026年10月2日 | 每日 |
| FXH · First Trust Exchange-Traded Alpha... | 1.49% | 67178 NS | 2026年7月31日 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1.27% | 11113 SH | 2026年10月2日 | 每日 |
| NUDV · Nushares ETF Trust | 1.09% | 2338 NS | 2026年7月31日 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.97% | 637 NS | 2026年7月31日 | N-PORT |
| SPLV · Invesco Exchange-Traded Fund Trus... | 0.88% | 263082 SH | 2026年10月2日 | 每日 |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.78% | 4469 SH | 2026年10月2日 | 每日 |
| JOET · Virtus ETF Trust II | 0.78% | 8139 NS | 2026年7月31日 | N-PORT |
| ESMV · iShares Trust | 0.70% | 236 SH | 2026年9月11日 | 每日 |
| QLV · FlexShares Trust | 0.63% | 4452 NS | 2026年7月31日 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0.60% | 1903 NS | 2026年7月31日 | N-PORT |
| COWZ · Pacer Funds Trust | 0.46% | 369448 NS | 2026年7月31日 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund ... | 0.43% | 8600 NS | 2026年7月31日 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund ... | 0.43% | 8453 NS | 2026年7月31日 | N-PORT |
| IYH · iShares Trust | 0.41% | 64629 SH | 2026年9月11日 | 每日 |
| VOE · VANGUARD INDEX FUNDS | 0.40% | 711079 SH | 2026年8月19日 | 每日 |
| FTA · First Trust Exchange-Traded Alpha... | 0.38% | 22688 NS | 2026年7月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.37% | 52313 NS | 2026年7月31日 | N-PORT |
| IMCV · iShares Trust | 0.36% | 18030 SH | 2026年9月11日 | 每日 |
| SUSA · iShares Trust | 0.34% | 59240 SH | 2026年9月11日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.34% | 330273 SH | 2026年8月19日 | 每日 |
| IXJ · iShares Trust | 0.32% | 58047 SH | 2026年9月11日 | 每日 |
| DFLV · Dimensional ETF Trust | 0.30% | 87905 NS | 2026年7月31日 | N-PORT |
| FEX · First Trust Exchange-Traded Alpha... | 0.30% | 19944 NS | 2026年7月31日 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.30% | 2178 NS | 2026年7月31日 | N-PORT |
| EQIN · Columbia ETF Trust I | 0.27% | 3540 NS | 2026年7月31日 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund ... | 0.26% | 9337 NS | 2026年7月31日 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund ... | 0.26% | 27542 NS | 2026年7月31日 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Inde... | 0.25% | 7574000 | 2026年10月2日 | 每日 |
| IWS · iShares Trust | 0.25% | 165299 SH | 2026年9月11日 | 每日 |
| ESUM · Strategy Shares | 0.24% | 1901 NS | 2026年7月31日 | N-PORT |
| SIZE · iShares Trust | 0.24% | 4359 SH | 2026年9月11日 | 每日 |
| VO · VANGUARD INDEX FUNDS | 0.23% | 2398948 SH | 2026年8月19日 | 每日 |
| VFMV · VANGUARD WELLINGTON FUND | 0.22% | 4307 SH | 2026年8月19日 | 每日 |
| RSP · Invesco Exchange-Traded Fund Trust | 0.20% | 829766 SH | 2026年10月2日 | 每日 |
| ACWV · iShares, Inc. | 0.20% | 28973 SH | 2026年9月11日 | 每日 |
| EUSA · iShares, Inc. | 0.19% | 16140 SH | 2026年9月11日 | 每日 |
| FAB · First Trust Exchange-Traded Alpha... | 0.19% | 1371 NS | 2026年7月31日 | N-PORT |
| IWR · iShares Trust | 0.19% | 452857 SH | 2026年9月11日 | 每日 |
| IMCB · iShares Trust | 0.18% | 12959 SH | 2026年9月11日 | 每日 |
| MTUM · iShares Trust | 0.16% | 168369 SH | 2026年9月11日 | 每日 |
| DFVX · Dimensional ETF Trust | 0.16% | 3609 NS | 2026年7月31日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.15% | 97399 NS | 2026年7月31日 | N-PORT |
| ESLG · Strategy Shares | 0.15% | 146 NS | 2026年7月31日 | N-PORT |
| XOEF · iShares Trust | 0.15% | 140 SH | 2026年9月11日 | 每日 |
| CATH · Global X Funds | 0.12% | 6867 NS | 2026年7月31日 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trus... | 0.12% | 165000 | 2026年10月1日 | 每日 |
| ROUS · Lattice Strategies Trust | 0.12% | 3633 NS | 2026年7月31日 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trus... | 0.11% | 115253 SH | 2026年10月2日 | 每日 |
| EVUS · iShares Trust | 0.11% | 1865 SH | 2026年9月11日 | 每日 |
| VIG · VANGUARD SPECIALIZED FUNDS | 0.10% | 625384 SH | 2026年8月19日 | 每日 |
| VYM · VANGUARD WHITEHALL FUNDS | 0.10% | 440583 SH | 2026年8月19日 | 每日 |
| DGRO · iShares Trust | 0.10% | 179879 SH | 2026年9月11日 | 每日 |
| EQAL · Invesco Exchange-Traded Fund Trus... | 0.09% | 3271 SH | 2026年10月2日 | 每日 |
| PFM · Invesco Exchange-Traded Fund Trust | 0.09% | 3153 SH | 2026年10月2日 | 每日 |
| VTV · VANGUARD INDEX FUNDS | 0.09% | 1051572 SH | 2026年8月19日 | 每日 |
| DXUV · Dimensional ETF Trust | 0.09% | 2092 NS | 2026年7月31日 | N-PORT |
| CRBN · iShares Trust | 0.09% | 4406 SH | 2026年9月11日 | 每日 |
| DCOR · Dimensional ETF Trust | 0.09% | 12279 NS | 2026年7月31日 | N-PORT |
| IVE · iShares Trust | 0.09% | 183297 SH | 2026年9月11日 | 每日 |
| IUSV · iShares Trust | 0.08% | 97344 SH | 2026年9月11日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.08% | 167227 NS | 2026年7月31日 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.08% | 25423 SH | 2026年8月19日 | 每日 |
| CHRI · Global X Funds | 0.08% | 27 NS | 2026年7月31日 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0.08% | 1095 NS | 2026年7月31日 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Inde... | 0.08% | 3155 SH | 2026年10月2日 | 每日 |
| SUSL · iShares Trust | 0.08% | 3907 SH | 2026年9月11日 | 每日 |
| ILCV · iShares Trust | 0.07% | 4337 SH | 2026年9月11日 | 每日 |
| DSI · iShares Trust | 0.07% | 16854 SH | 2026年9月11日 | 每日 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.07% | 66643 SH | 2026年8月19日 | 每日 |
| IWD · iShares Trust | 0.07% | 245078 SH | 2026年9月11日 | 每日 |
| HDUS · Lattice Strategies Trust | 0.07% | 586 NS | 2026年7月31日 | N-PORT |
| EGLE · Global X Funds | 0.06% | 6 NS | 2026年7月31日 | N-PORT |
| GLBL · Pacer Funds Trust | 0.06% | 3 NS | 2026年7月31日 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.06% | 24838 SH | 2026年10月2日 | 每日 |
| RWL · Invesco Exchange-Traded Fund Trus... | 0.06% | 24491 SH | 2026年10月2日 | 每日 |
| DFSU · Dimensional ETF Trust | 0.05% | 5056 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.05% | 26447 NS | 2026年7月31日 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Inde... | 0.05% | 9857 SH | 2026年10月2日 | 每日 |
| TOPC · iShares Trust | 0.05% | 68 SH | 2026年9月11日 | 每日 |
| XVV · iShares Trust | 0.04% | 1285 SH | 2026年9月11日 | 每日 |
| XYLD · Global X Funds | 0.04% | 6096 NS | 2026年7月31日 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trus... | 0.04% | 3119 SH | 2026年10月2日 | 每日 |
| BKLC · BNY Mellon ETF Trust | 0.04% | 9574 NS | 2026年7月31日 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund ... | 0.04% | 15319 NS | 2026年7月31日 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.04% | 2875103 SH | 2026年8月19日 | 每日 |
| VV · VANGUARD INDEX FUNDS | 0.04% | 129285 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.04% | 24972 SH | 2026年8月19日 | 每日 |
| TOV · EA Series Trust | 0.04% | 426 NS | 2026年7月31日 | N-PORT |
| PTLC · Pacer Funds Trust | 0.04% | 5593 NS | 2026年7月31日 | N-PORT |
| VOTE · TCW ETF Trust | 0.04% | 1876 NS | 2026年7月31日 | N-PORT |
| XYLG · Global X Funds | 0.04% | 109 NS | 2026年7月31日 | N-PORT |
| XCLR · Global X Funds | 0.04% | 6 NS | 2026年7月31日 | N-PORT |
| IVV · iShares Trust | 0.04% | 1392389 SH | 2026年9月11日 | 每日 |
| PBP · Invesco Exchange-Traded Fund Trust | 0.04% | 655 SH | 2026年10月2日 | 每日 |
| PBUS · Invesco Exchange-Traded Fund Trus... | 0.04% | 19201 SH | 2026年10月2日 | 每日 |
| XTR · Global X Funds | 0.04% | 8 NS | 2026年7月31日 | N-PORT |
| ILCB · iShares Trust | 0.04% | 2144 SH | 2026年9月11日 | 每日 |
| XRMI · Global X Funds | 0.04% | 82 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.04% | 33588 NS | 2026年7月31日 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.04% | 417 NS | 2026年7月31日 | N-PORT |
| QDPL · Pacer Funds Trust | 0.04% | 2663 NS | 2026年7月31日 | N-PORT |
| IWB · iShares Trust | 0.04% | 76198 SH | 2026年9月11日 | 每日 |
| VOXP · Advisors Series Trust | 0.04% | 9 NS | 2026年7月31日 | N-PORT |
| IYY · iShares Trust | 0.04% | 4688 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.03% | 30298 SH | 2026年9月11日 | 每日 |
| ITOT · iShares Trust | 0.03% | 141099 SH | 2026年9月11日 | 每日 |
| PHDG · Invesco Actively Managed Exchange... | 0.03% | 88 SH | 2026年10月2日 | 每日 |
| HCMT · Direxion Shares ETF Trust | 0.03% | 772 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.03% | 3515122 SH | 2026年8月19日 | 每日 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.03% | 18213 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.03% | 9300 SH | 2026年8月19日 | 每日 |
| SPXL · Direxion Shares ETF Trust | 0.03% | 8650 NS | 2026年7月31日 | N-PORT |
| URTH · iShares, Inc. | 0.03% | 10177 SH | 2026年9月11日 | 每日 |
| TILT · FlexShares Trust | 0.03% | 2686 NS | 2026年7月31日 | N-PORT |
| TOK · iShares Trust | 0.03% | 292 SH | 2026年9月11日 | 每日 |
| ACWI · iShares Trust | 0.03% | 36161 SH | 2026年9月11日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.02% | 95097 SH | 2026年8月19日 | 每日 |
| DYNF · BlackRock ETF Trust | 0.02% | 34844 SH | 2026年9月11日 | 每日 |
| GTO · Invesco Actively Managed Exchange... | 0.00% | 1000 | 2026年9月30日 | 每日 |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 2026年7月15日 | 每日 |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 每日 |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 2026年7月15日 | 每日 |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 每日 |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 每日 |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月15日 | 每日 |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 每日 |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 2026年7月30日 | 每日 |
| VCEB · VANGUARD WORLD FUND | · | · | 2026年7月30日 | 每日 |
DGX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 23 位分析师
买入
中位数目标
$250.00
+7.1%
6 26.1%
强烈买入
7 30.4%
买入
10 43.5%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
15 位分析师 · 2026-10-04平均目标 $247.73 +6.2%
现在
当前价格 $233.33
最低$204.00
平均值$247.73
最高$265.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | · |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | · |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | · |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | · |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| HIMS | · | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| CHE | · | 23.3 | 4.1% | 10.5% | 24.4% | · |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 七月 23, 2026 申报